Xavier Montalbán
0000-0002-0098-9918
Publication & Citation Trends
Publications
0 total
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial
Cited by 2
Semantic Scholar
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial.
Cited by 0
Semantic Scholar
Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort
Cited by 4
Semantic Scholar
Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study OA
Cited by 13
Semantic Scholar
Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension OA
Cited by 19
Semantic Scholar
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study OA
Cited by 19
Semantic Scholar
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study OA
Cited by 21
Semantic Scholar
Research Topics
Multiple Sclerosis Research Studies
(765)
Peripheral Neuropathies and Disorders
(217)
Systemic Lupus Erythematosus Research
(123)
Polyomavirus and related diseases
(117)
Rheumatoid Arthritis Research and Therapies
(86)
Affiliations
University of Siena
Northwestern University
University of North Carolina at Chapel Hill
Oxford Instruments (United Kingdom)
Universitat de Vic - Universitat Central de Catalunya